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I. Abstract 
 Triclosan is an antibacterial compound which is commonly used in a number of consumer 
products. In its native form, triclosan is an irritant to the lining of the bowel. Bowel irritation 
caused by the reactivation of triclosan can worsen the symptoms of inflammatory bowel disease 
(IBD).1 Over 1.6 million Americans are believed to have IBD.2 Therefore, it is of great interest 
and necessity to understand the reactivation pathway of triclosan in the gut by a class of gut 
bacterial enzyme known as β-glucuronidases (GUS). This study focuses on elucidating the 
structure and key residues responsible for the reactivation of triclosan by GUS through in silico 
and in vitro methods. Preliminary catalytic efficiency data regarding triclosan processing 
efficiency was collected in order to better understand which GUS were the most successful at 
reactivating triclosan. The GUS which were the most successful at processing triclosan were then 
examined via in silico methods. In order to visualize the structure of these GUS, X-ray 
crystallography was performed to determine two novel GUS structures. With structures in hand, 
Schrödinger molecular docking suite was used to computationally model the ligand binding and 
interactions within the active site. Using site directed mutagenesis, we then probed the key residues 
of interest which had been identified by docking based on proximity to the ligand and hypothesized 
chemical interactions. This resulted in the discovery of key active site residues which are 
significant in the reactivation of triclosan by loop 1 and FMN-binding GUS. The findings of this 
study will help to better characterize the reactivation of the environmental risk factor triclosan by 
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II. Introduction  
Inflammatory bowel disease (IBD) is characterized by chronic inflammation to the human 
gastrointestinal tract, particularly the bowel. Symptoms of IBD include diarrhea, rectal bleeding, 
abdominal pain, fatigue, unintended weight loss, and malnutrition. Beyond the physical impacts 
caused by IBD, patients may also suffer from extreme social anxiety, embarrassment, reduced 
quality of life, and depression. While there are some known treatments that can alleviate the 
severity of IBD symptoms, there is no known cure.3 Two common forms of IBD are Chron’s 
disease and ulcerative colitis.4 Chron’s disease is characterized by inflammation to the lining of 
any region of the gastrointestinal tract and may include damage to deeper tissue.4 Ulcerative colitis 
is characterized by sores and ulcers along the most outer layers of the large intestine and rectum.4 
The causes of IBD are not fully understood; however, it is known that some factors may contribute 
to an increased risk of developing IBD. In some cases, IBD may be caused by an immune system 
malfunction brought on by a bacterial or viral infection. Other risk factors include the use of 
antibiotics and nonsteroidal anti-inflammatory medications. Additionally, there is some evidence 
to support that genetic predisposition may play a role in IBD. More interestingly it has been 
documented that environmental risk factors may contribute to IBD. One known environmental 
toxin that is a risk factor in IBD is triclosan.5 
Triclosan is a commonly used antimicrobial agent which can be found in a variety of common 
household materials such as toothpaste, makeup, children’s toys, medical supplies, and 
detergents.6 Upon contact or consumption, triclosan is absorbed into the blood stream and 
metabolized in the liver by UDP-glucuronosyltransferases which append a glucuronic acid moiety. 
This process converts the native triclosan compound to the phase II metabolite triclosan-
glucuronide. From the liver the metabolite travels to and is excreted via the gastrointestinal tract. 
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β-glucuronidases (GUS) are bacterial enzymes which reside in the gut and can cleave glucuronic 
acid from triclosan-glucuronide, returning the compound to its native form prior to excretion. 
Reactivation of the parent triclosan compound is problematic, as research has indicated that 
triclosan in its native form is an inflammatory agent to the lining of the bowel.7  
 
 
Figure 1: Triclosan metabolism and reactivation pathway within the human body. 
Bowel irritation due to the reactivation of triclosan by GUS can exacerbate the symptoms of 
IBD.5 In 2014 it was estimated that 1.6 million Americans currently have IBD.8 The population of 
affected individuals continues to rise as over fifty thousand new cases of IBD are diagnosed 
annually.5 Additionally, the financial burden and cost of care for patients with IBD can be up to 
three-fold higher than that of patients without IBD.9 The average cost of health care for a person 
without IBD was found to be approximately $7,000 annually while a person with IBD faced an 
average annual cost of $23,000.9 In the United States it is estimated that up to $28 billion are spent 
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annually on IBD related expenses including cost of care and testing.10 It is important that the 
reactivation pathway of triclosan by GUS be better understood, as this is a source of both physical 
suffering and financial hardship for many patients diagnosed with IBD. 
The human microbiome contains enzymes that perform a variety of metabolic processes. One 
known class of such enzymes are GUS, which cleave a glucuronic acid molecule from larger 
glucuronide substrates. 297 GUS have been discovered through data collection from the human 
microbiome project database; however, fewer than 10% of these GUS have identified structures 
and functions.11 GUS structure varies widely meaning that substrate specificity also varies 
significantly. GUS have been previously characterized based on their general structure into 
different loop categories.12 The structural differences of the loops present in the GUSs allow for 
processing of different compounds based on size, conformation, and polarity.12  
 
Of the no-loop GUS which have been discovered, there are 15 GUS of similar structure 
that have the ability to bind the cofactor flavin mononucleotide (FMN) at an allosteric site 30 Å 
from the active site.11 Very little is known about the implications of FMN-binding GUS.8 
Interestingly, these FMN-binding GUS have an unresolved C-terminal domain. This is unique as 
the C-terminal domain is hypothesized to play a role in FMN-binding GUS ability to process small 
glucuronic acid substrates. FMN-binding GUS selectively process small substrates such as the 
Table 1 
Table 1: Loop Types and Descriptions 
Loop classifications are made based on the location and number of residues within the loop. 
The size of the loop is correlated with the types of substrates which each loop can process. 
These characterizations were founded on the basis of E. coli GUS. 
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antimicrobial agent and environmental toxin, triclosan.5,6 This ability is of particular interest 
because typically no loop GUS such as FMN-binding GUSs are generally unable to process small 
substrates; however, FMN-binding GUS maintain this ability. 
 
Figure 2: The FMN-binding GUS F. prausnitzii L2-6 GUS. 
The FMN-binding site (cyan) is located 30 Å from small substrate active site (orange). The C-
terminus (red) can be seen located opposite of the FMN-binding site. The N-terminus (magenta) 
is located in immediate proximity to the FMN-binding site. The FMN substrate is shown in the 
yellow ball structure.11 
Through this study, I aim to isolate specific loop classes of GUS which are successful at 
reactivating triclosan. I will then elucidate the key residues of GUS that facilitate triclosan-
glucuronide cleavage in addition to better characterizing the larger role which GUS plays in the 
reactivation of triclosan in the gut.  
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In this study we used data from a previously conducted UDH/NAD+ coupled assays to 
indirectly postulate the relative processing ability of GUS by loop class.13 We conducted a catalytic 
efficiency assays to determine the relative processing ability of a panel of GUS across all loop 
classes. GUS which are representative of the most successful triclosan reactivating classes were 
selected for in silico testing using Schrödinger Molecular Docking Suite. These GUS underwent 
computational ligand docking in order to reveal the active site residues within the triclosan binding 
pocket. Hypotheses were made to predict the key active site residues which may contribute to the 
triclosan processing ability of each GUS. Key residues were selected from two GUS – one FMN-
binding GUS and one loop 1 GUS – and probed for significance via site directed mutagenesis. 
These findings confirmed that key residues present in the GUS active site are significant to the 
function of these GUS and their ability to successfully reactivate the inflammatory agent, triclosan. 
Understanding the role of GUS structure in the triclosan reactivation pathway in turn revealed key 
characteristics of GUS which may be responsible for exacerbating the symptoms of IBD.  
III. Materials and Methods 
Expression and Purification of GUS – A panel of GUS were selected, expressed, and purified 
for testing using standard methods. Genes encoding for the GUS of interest were selected, 
optimized for expression, and inserted into cloning vectors by Biobasic.8 Plasmids were 
transformed by heat-shock into BL21-DE3 E. coli cells for expression. Protein was expressed and 
purified using standard methods.8 
HPLC Triclosan Processing Catalytic Efficiency Assay of GUS – An in vitro HPLC triclosan 
processing assay was performed in order to determine the catalytic efficiency of a panel of GUS 
with triclosan-glucuronide. Each assay mixture contained a volume of 10 µL GUS (final 
concentrations varied between 10-50 nM), 30 µL triclosan-glucuronide substrate (final 
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concentrations between 30-120 µM), and 10 µL corresponding assay buffer (50 mM HEPES, 50 
mM NaCl, various pH or 50 mM sodium acetate, 50 mM NaCl, various pH). Control reactions 
replaced 10 µL GUS volume with 10 µL buffer. Reactions were allowed to proceed to appropriate 
time point (1-5 minutes) and then quenched with 50 µL of 25% trichloroacetic acid. The quenched 
reaction samples were then centrifuged for 10 minutes at 13,000 RPM. The supernatant was 
collected and used for HPLC analysis on an Agilent InfinityLab Poroshell 120 C18 column 
(dimensions 4.6 x 100 mm, particle size 2.7 µM). The column temperature was set to 30 °C. The 
flow rate was set to 0.9 mL/min with an injection volume of 40 µL.  
The column conditions were set to flow at 98% A (water with 0.1% formic acid) with 2% B 
(acetonitrile with 0.1% formic acid) for two minutes. Then, a linear gradient was set to flow up to 
98% B over a 10-minute time span. The 90% B conditions were maintained for 4 minutes. The 
conditions were then returned to 98% A for 1 minute and then re-equilibrated at 98% A for two 
minutes. Concentrations of triclosan-glucuronide were determined using a standard curve of 
triclosan-glucuronide (0-250 µM). 
All reaction curves were fit using a prepared linear regression. Calculated initial velocities 
from this data were plotted against substrate concentration. This produced a calculation of kcat/KM 
which revealed catalytic efficiency.  
X-ray Crystallography Crystal Optimization, Preparation, and Data Collection – Structures 
of triclosan reactivating FMN-binding GUS were resolved through standard X-ray 
Crystallography techniques. Commercially-available crystallography broad screens were used to 
obtain initial crystal hits. The conditions which successfully produced initial hits were then 
optimized to obtain larger and better structured diffracting crystals which were analyzed. 
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Optimized crystals were collected and sent to the GM-CA beamline for data collection. Diffraction 
data was then processed using HKL3000 and Phenix.  
Schrodinger Molecular Docking Suite Induced Fit Ligand Docking Protocol – To analyze the 
proteins in the Schrödinger Molecular Docking Suite, the structures had to be prepared. Initially I 
gathered the seven structures from the Protein Data Bank or from newly solved crystal structures 
by Gibbs. Once collected, the structures were uploaded into PyMOL. I generated the symmetry 
mates to construct the appropriate quaternary structure for each of the proteins. All water 
molecules and metal ions were manually deleted from the structure in addition to any bound 
ligands. These files were aligned with one another and then exported.  
The exported files were loaded into a Schrödinger project window for final preparation 
before docking. Proteins were individually minimized using the Protein Preparation Wizard 
application. Hydrogen-bonds were optimized and the pH was optimized. Additionally, the 
triclosan-glucuronide ligand was prepared and optimized using the Ligand Preparation Wizard 
application for use in computational docking tests.  
Once prepared, the seven proteins were individually modeled and tested using the 
Schrödinger Induced Fit Docking program. Initially each protein underwent a sub-job as part of 
this program known as glide docking. In this computational model the protein maintained a rigid 
structure while the ligand was given flexibility parameters in order to bend and conform to 
identify possible conformations within the protein active site. Once completed, the model was 
then evaluated using the sub-job program of induced fit docking. In this test, both the protein and 
ligand are given flexibility parameters to bend and determine likely active site conformations.  
After undergoing both docking programs, Schrödinger generated a variety of likely 
candidates for possible ligand conformations at the active site. The top five candidate 
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conformations based on the parameters of IFD score, steric interactions, and ligand orientation 
were exported for evaluation in PyMOL. 
PyMOL Visualization of Active Site Residues – Once in PyMOL, projections were made to 
determine key active site residues. These predictions were based on proximity to the glucuronic 
acid moiety as well as favorable interactions such as pi-pi staking with the bound triclosan- 
glucuronide. The active site residues were color coded. Mutants were then designed based off of 
these visualizations. 
Preparation, Expression, and Purification of GUS Mutants – Based on key residue predictions, 
we developed primers and expressed the mutant strains of protein utilizing standard methods 
(Table 2). Site-directed mutagenesis was performed using standard methods.8 Primers for site-
directed mutagenesis were purchased from Integrated DNA Technologies. Mutations were 
confirmed via DNA sequencing by Eton Bioscience. Plasmids were transformed by heat-shock 
into BL21-DE3 E. coli cells for expression. Protein was expressed and purified using standard 
methods.8 
Table 2: Primer Sequences 
Designed Primer sequences for each of the designed mutants to test the significance of key 
residues of interest.   
GUS and Residue Mutation Forward Primer (5’ è 3’) Reverse Primer (5’ è 3’) 
UNC361-01 M362A gaagtgcctgctgtcggttttgcggaatctaccatgaact agttcatggtagattccgcaaaaccgacagcaggcacttc 
UNC361-01 M454A tacctacgcggttgtggcgatgagcctgccgaac gttcggcaggctcatcgccacaaccgcgtaggta 
UNC361-01 M455A ctacgcggttgtgatggcgagcctgccgaacaac gttgttcggcaggctcgccatcacaaccgcgtag 
UNC361-01 Y479A aaccgttactatggttgggccgttatgggtggcatggg cccatgccacccataacggcccaaccatagtaacggtt 
UNC361-30 F406A cgtgatggcggacgtggccatgctggaaacggat atccgtttccagcatggccacgtccgccatcacg 
UNC361-30 Y430A caacctgtacttcggttgggccatcggtgaactggatcag ctgatccagttcaccgatggcccaaccgaagtacaggttg 
UNC361-30 L635STOP cccggattacattttcaactaacagggtgacgttg caacgtcaccctgttagttgaaaatgtaatccggg 
 
HPLC Triclosan Processing Catalytic Efficiency Assay of Mutant GUS – Then, we performed 
the above outlined catalytic efficiency assay in order to determine key residues of significance to 
each respective protein’s catalytic function in processing triclosan-glucuronide. 
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IV. Results and Discussion 
A previous study had been conducted to survey the triclosan reactivation capabilities of a 
panel of 32 GUS.13 A variety of GUS across each of the different GUS loop classes were 
selected for testing in order to holistically characterize triclosan reactivating GUS. This study 
involved the use of an assay which measured relative triclosan reactivation with a UDH-NAD+ 
coupled assay (Figure 12). The data from this assay indicated that in comparison to other GUS 
loop classes, loop 1 and FMN-binding GUS were significantly more successful at reactivating 
triclosan in comparison to loop 2, mini loop 1, mini loop 2, mini loop 1,2, and no loop GUS. 
 
Figure 3: Triclosan-glucuronide Processing in a Panel of GUS. 
Previously conducted test to screen for the success of triclosan reactivation by a panel of 32 
GUS. These GUS were from each of the identified classes and provided insight into the relative 
success of triclosan reactivation based on GUS loop class. Significant findings were found 
relative to triclosan reactivation by Loop 1 and FMN-binding GUS. 
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Based on the findings of the UDH-NAD+ coupled assay and previously established GUS 
substrate specificity by loop class, an in vitro HPLC triclosan-glucuronide assay was performed 
in order to determine the catalytic efficiency of a panel of the most successful triclosan 
processers. The classes selected for testing were loop 1, loop 2, and FMN-binding GUS. The 
results from this experiment indicated that FMN-binding GUS and loop 1 GUS demonstrated 
relatively high catalytic efficiencies in triclosan-glucuronide processing in comparison to loop 2 
GUS. This finding was somewhat confounding based on previously characterized substrate 
specificity of GUS by loop class.12 Loop 1 GUS are known to preferentially process small 
glucuronidated substrates, as are loop 2 GUS. However, FMN-binding GUS are known to 
preferentially process large heparan substrates. Despite this, FMN-binding GUS maintain the 
ability to successfully reactivate triclosan as demonstrated by the findings of this assay.   
 
Figure 4: Catalytic Efficiencies of FMN-binding GUS 
These data provided the basis for computational modeling selection of the active site residue and 
bound triclosan-glucuronide ligand conformation for loop 1 GUS and FMN-binding GUS. 
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Based on the findings of this triclosan-glucuronide catalytic efficiency assay, seven GUS 
were selected for further testing. Because loop 1 and FMN-binding GUS exhibited the highest 
overall success at reactivating triclosan, the seven selected GUS were exclusively from these two 
classes. Loop 1 and FMN-binding GUS demonstrated a range of efficiency at triclosan 
reactivation amongst themselves. Four highly successful (“fast”) triclosan processing GUS and 
three of the least successful (“slow”) triclosan reactivating GUS were selected for structural 
examination through in silico testing and visualization. The examination of the structure for both 
successful triclosan processing GUS and less successful triclosan processing GUS helped to 
better characterize which active site residues are significant in the triclosan reactivation pathway.  
Table 3: Identification of selected GUS by loop class, formal name, relative processing “speed” 
and referenced abbreviation. 
GUS Class Name Abbreviation Relative Processing Speed 
FMN-binding R. hominis 3 UNC30 Fast 
Loop 1 Eubacterium eligens Ee Fast 
Loop 1 F. prausnitzii 2-L1 UNC01 Fast 
FMN-binding Ruminococcus gnavus 3 Rg3 Fast 
Loop 1 Faecalibacterium prausmitzii Fp Slow 
Loop 1  Escherichia coli Ec Slow 
FMN-binding Roseburia hominis 2 Rh2 Slow 
 
 The seven selected GUS were then analyzed using the Schrödinger Molecular Docking 
Suite. The output data from Schrödinger provided insight into the likely conformations of the 
ligand as well as the active site residues key to the processing of triclosan glucuronide. Potential 
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interactions as well as proximity to the docked ligand were considered. Based on the initial 
findings from Schrödinger, approximately three unique residues were predicted to play a 
significant role in triclosan glucuronide processing in each protein. Initially all of the active site 
residues were modeled for these seven proteins and the catalytically relevant, conserved active 
site residues were identified. The non-conserved active site residues between the seven proteins 
were examined closely for potential ligand interactions. Residues of significance were identified 
based on proximity of the residues to the ligand binding site. 
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Figure 5: Triclosan-glucuronide Ligand Docking in 7 GUS Structures. 
The conserved catalytic glutamate active site residues are displayed in grey. Predicted key residues 
in the processing of the triclosan glucuronide substrate (blue) are cyan colored. The hypothesized 
key residues have been labeled in addition to the two conserved catalytic glutamates. (A) UNC 30 
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It was observed that GUS which were “fast” triclosan processors were observed to exhibit 
favorable pi-stacking interactions as well as minimal binding-pocket obstruction by residues. The 
GUS which were “slow” triclosan-glucuronide processors exhibited active site residues which may 
have interfered with the ligand’s ability to favorably orient in the binding pocket. Steric hindrance 
is one significant predicted interference that is hypothesized to be at least partially responsible for 
the observed results.  
 
Figure 6: Relatively fast triclosan reactivating GUS. 
The conserved catalytic glutamate active site residues are displayed in grey. Predicted key residues 
in the processing of the triclosan glucuronide substrate (blue) are cyan colored. The hypothesized 
key residues have been labeled in addition to the two conserved catalytic glutamates. 
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Figure 7: Relatively slow triclosan reactivating GUS.  
The conserved catalytic glutamate active site residues are displayed in grey. Predicted key residues 
in the processing of the triclosan glucuronide substrate (blue) are cyan colored. The hypothesized 
key residues have been labeled in addition to the two conserved catalytic glutamates. 
 
The active site residues for UNC01 GUS and UNC30 GUS were examined. Predictions were 
made as to which residues for each of these proteins might be significant to the successful 
processing of triclosan glucuronide. These two proteins were focused on more heavily as the 
ultimate aim of this project was to better characterize FMN-binding GUS processing of triclosan-
glucuronide verses loop 1 GUS processing. Based on the determined key residues for each of 
these proteins, mutations were designed in order to test the significance of each residue in the 
processing of triclosan glucuronide. All of the selected residues were considered to be significant 
in the processing of triclosan glucuronide. 
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Figure 8: The predicted significant active site residues for UNC 30 GUS (at left) and UNC 01 
GUS (at right). 
Conserved active site residues are displayed in grey. Predicted key residues and corresponding 
measurements to the triclosan glucuronide substrate (blue) are cyan colored. The hypothesized key 
residues have been labeled in addition to the two conserved catalytic glutamates. 
 
Predicted residues for UNC01 and UNC30 GUS have been displayed pictorially in a figure 
above. Corresponding mutations for each of the residues can be found in a table below. It is 
significant to note that an early stop codon was designed as a mutation for the C-terminal domain 
of the UNC30 FMN-binding GUS. It has been observed that the C-terminal domain is significant 
in the role of FMN-binding GUS function, though the mechanism giving rise to this significance 
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Table 4: Identified Key Residues and Designed Mutations. 
Key residues predictions and corresponding mutations for UNC30 GUS and UNC01 GUS. 
Protein Name GUS Class Key Residue and Mutation 













Of the predicted key residues and corresponding mutations, five designed mutations were 
determined to have a significant impact on the function of triclosan glucuronide processing. This 
finding suggested that these four residues and the C-terminal domain are significant to the 
function of the active site in reactivating triclosan. The absence of these resides or the C-terminal 
domain was detrimental to the catalytic function of these proteins. Two of the predicted 
mutations for UNC 30 GUS resulted in increased triclosan glucuronide processing. These 
residues likely caused steric hindrance to the active site ligand interaction. This made it possible 
for their absence to positively impact catalytic processing ability as their replacement with the 
less bulky amino acid alanine alleviated the steric hindrance of triclosan-glucuronide binding. 
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Figure 9: Catalytic Efficiency Testing Results for UNC1 (at right) and UNC30 (at left) GUS 
Mutants. 
The tested mutations associated with key residues of significance are displayed with an asterisk. 
Note that performance above that of the wild type catalytic efficiency demonstrates that the 
presence of the residue hindered processing of triclosan glucuronide. 
 
These findings indicate that within loop 1 and FMN-binding GUS there are key active site 
residues which contribute to the overall function of these enzymes. Some residues within the 
active site of the GUS are responsible for their ability to reactive triclosan while other residues 
may contribute to steric hindrance or other inhibitory interaction. Overall these findings indicate 
that loop 1 and FMN-binding GUS contribute to the toxification of triclosan and subsequent 
impact on IBD. 
V. Conclusion 
Ultimately it was determined that FMN-binding GUS and loop 1 GUS are successful at 
processing triclosan glucuronide due to key residues present at the active site which can 
participate in favorable interactions. Successful modeling of active site conformation to the 
triclosan glucuronide ligand in a variety of proteins provided an accurate model from which to 
UNC 30 UNC 01 
 - 21 - 
predict key residues of interest. Based on these predictions, site-directed mutagenesis was 
successfully performed to tested the impact of these residues. It was determined that projected 
active site residues had significant impact on the catalytic function for both loop 1 and FMN-
binding GUS. These findings suggest that FMN-binding GUSs and loop 1 GUSs are significant 
in the processing of triclosan glucuronide and therefore play a role in triclosan toxification. Such 
reactivation by these proteins is directly relevant to the triclosan induced irritation to the lining of 
the bowel.  
VI. Contribution of Findings to Additional Investigation13 
Based on the findings of our investigation, a mouse model study was designed and conducted 
to better evaluate the significance of loop 1 and FMN-binding GUS in triclosan toxification and 
bowel irritation. Mice have a similar GUS composition to humans, allowing for triclosan 
toxification to be comparably examined. 
A group of mice was given both triclosan and a loop 1 and FMN-binding GUS inhibitor. This 
inhibitor was used in order to stop the function of these GUS classes. This group of mice 
demonstrated less bowel irritation than mice who were only given triclosan without the inhibitor.  
 
Figure 10: Proposed Inhibition of GUS by the Inhibitor UNC10201652.  
Inhibitor UNC10201652 is believed to block the function of GUS by interrupting the catalytic 
mechanism at the active site. By blocking the function of loop 1 and FMN-binding GUS, the 
reactivation of triclosan may be avoided and eliminate bowel irritation.  
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Because the inhibitor selectively stops the function of only loop 1 and FMN-binding GUS, 
these findings suggest that loop 1 and FMN-binding GUS are a significant player in the 
reactivation of triclosan and the subsequent occurrences of bowel irritation.  
VII. Future Directions 
Many other classes of GUS have been extensively studied, yielding much information about 
their function. However, little is known about the substrate specificity of FMN-binding GUS.11 
The role of FMN in GUS is not known. It has been proposed that FMN provides structural stability 
to GUS. Preliminary studies suggest that the catalytic function of GUS is unchanged by the absence 
of FMN.11 However, little has been done to uncover the explicit role of FMN in GUS. The 
structures of all FMN-binding GUSs have yet to be resolved; however, it is projected that the 
FMN-binding site maintains a conserved tertiary structure.6  
Furthermore, during this investigation an interesting characteristic was observed for FMN-
binding GUS. The C-terminal domain plays a key role in the catalytic function of the tested FMN-
binding GUS. The C-terminal deletion mutant displayed markedly decreased catalytic function. 
This observation leads to the postulation that the C-terminal domain may be significant to the 
function of these GUS.6  
To better understand the role of FMN in GUS function, the remaining unresolved FMN-
binding GUS structures could be determined utilizing X-ray crystallography techniques. The small 
substrate processing efficiency of FMN-binding GUS would then be examined using a triclosan-
glucuronide processing assay. This assay would be useful in observing the significance of the C-
terminal domain as well as the FMN-binding abilities of these GUS on GUS function. This would 
provide a framework for better understanding the role of FMN in GUS function. Additionally, it 
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would be beneficial to conduct structure-function analyses to further characterize the relationship 
of GUS FMN-binding ability to overall GUS function.  
VIII. Supplemental Information and Figures 
 
Figure 11: Catalytic Glutamate Cleavage of Glucuronic Acid from Substrate in GUS.  
This image depicts the cleavage of a glucuronic acid moiety by GUS which relies on two catalytic 
glutamates that are conserved in all GUS active sites. This figure is of E. eligens GUS. The 
catalytic glutamate 516 (hot pink) acts as a nucleophile while the catalytic glutamate 425 (purple) 
acts as an acid/base. This is the hypothesized mechanism of glucuronide cleavage by GUS. 14 
 
 
Figure 12: UDH/NAD+ Coupled Assay Outline 
This assay functions by indirectly measuring glucuronic acid cleavage from triclosan by GUS 
through the production of NADH+H+. Triclosan in its native form is converted to glucaro-1,5-
lactonoe by urinate dehydrogenase. Through this process, NAD+ is reduced to NADH+H+ which 
absorbs light at 340 nm. An absorbance measurement can be taken in order to indirectly measure 
triclosan-glucuronide processing.13 
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Figure 13: (A) Structure of the Loop 1 GUS Inhibitor UNC10201652. (B) 
This GUS inhibitor UNC10201652 (A) is successful at inhibiting the function of Loop 1 and 
FMN-binding GUS. The proposed mechanism of inhibition is displayed in figure 13 (B). The 
piperazine linked inhibitor is successful at interrupting the normal catalytic mechanism of the 
catalytic glutamates. This prevents the regeneration of the native compound by intercepting the 
GUS-glucuronic acid catalytic intermediate.14 
A 
B 
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Figure 14: Graphical Model of Mouse Trials to Examine Triclosan Reactivation by Loop 1 and 
FMN-binding GUS.  
The mouse models indicated that when a mouse was given triclosan in the absence of the 
inhibitor, bowel irritation occurred. However, when a mouse was given triclosan and the loop 1 
and FMN-binding GUS inhibitor UNC10201652, bowel irritation was not prominent. These 
findings indicate that loop 1 and FMN-binding GUS are responsible for the reactivation of 
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